#1 Clinical Trials Search in Europe

Intestifix

Recent clinical trials are investigating the potential of Intestifix, a fecal microbiota transfer (FMT) treatment, for various digestive and liver conditions. These studies aim to assess the safety, feasibility, and efficacy of Intestifix in treating Crohn’s disease, advanced liver cancer, and cirrhosis with ascites. The trials explore how Intestifix may help maintain remission, overcome treatment resistance, and address immune activation in these challenging medical conditions.

Table of Contents

What is INTESTIFIX?

INTESTIFIX is an innovative medical treatment that uses fecal microbiota transfer (FMT) to potentially treat various gastrointestinal and liver conditions. FMT involves transferring beneficial gut bacteria from healthy donors to patients with certain medical conditions[1]. INTESTIFIX comes in the form of capsules containing processed stool from carefully screened healthy donors.

How does INTESTIFIX work?

INTESTIFIX works by introducing healthy gut bacteria into the patient’s digestive system. This process, known as fecal microbiota transfer (FMT), aims to restore balance to the gut microbiome – the community of microorganisms living in our intestines. A healthy gut microbiome is crucial for proper digestion, immune function, and overall health[1].

In some medical conditions, the gut microbiome can become imbalanced or disrupted. By introducing beneficial bacteria from healthy donors, INTESTIFIX may help restore a healthier balance of gut bacteria, potentially improving symptoms and overall health[2].

What conditions can INTESTIFIX potentially treat?

Based on ongoing clinical trials, INTESTIFIX is being studied for its potential to treat several conditions:

  • Crohn’s Disease: A type of inflammatory bowel disease that can affect any part of the digestive tract[1].
  • Liver Cancer (Hepatocellular Carcinoma): A type of cancer that starts in the liver[2].
  • Liver Cirrhosis with Ascites: A condition where the liver is severely scarred, leading to fluid buildup in the abdomen (ascites)[3].

It’s important to note that while these studies are promising, INTESTIFIX is still considered an experimental treatment for these conditions.

How is INTESTIFIX administered?

INTESTIFIX is administered orally in the form of capsules. The dosage and duration of treatment may vary depending on the specific condition being treated and the individual patient’s needs. In clinical trials, the following dosing regimens have been used:

  • For Crohn’s Disease: Up to 50 grams total over a 2-month period[2].
  • For Liver Cancer: Up to 25 grams daily for up to 2 months[2].
  • For Liver Cirrhosis with Ascites: Up to 8 capsules daily for 3 days[3].

Always follow your healthcare provider’s instructions regarding dosage and administration.

Current Clinical Trials

INTESTIFIX is currently being studied in several clinical trials:

  1. EEN-RICH study: This trial is investigating the use of INTESTIFIX in maintaining remission in children and adults with Crohn’s disease after treatment with exclusive enteral nutrition[1].
  2. FLORA study: This trial is studying the combination of INTESTIFIX with other treatments (vancomycin, atezolizumab, and bevacizumab) in patients with advanced liver cancer[2].
  3. TransImmune study: This trial is evaluating the use of INTESTIFIX to treat immune activation in patients with liver cirrhosis and ascites[3].

Safety and Side Effects

As with any medical treatment, INTESTIFIX may cause side effects. The ongoing clinical trials are carefully monitoring the safety of INTESTIFIX. Some potential side effects being monitored include:

  • Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea)
  • Infections
  • Allergic reactions

It’s important to note that the full safety profile of INTESTIFIX is still being established through these clinical trials[1][2][3].

Conclusion

INTESTIFIX represents a promising new approach to treating various gastrointestinal and liver conditions using fecal microbiota transfer. While the results of ongoing clinical trials are eagerly awaited, it’s important to remember that INTESTIFIX is still an experimental treatment. If you have any of the conditions mentioned and are interested in INTESTIFIX, discuss it with your healthcare provider to understand if it might be an appropriate option for you in the future.

Trial Name Condition Main Objective Key Endpoints
EEN-RICH Study Crohn’s Disease Assess safety, feasibility, and efficacy of multi-donor FMT for maintaining remission after EEN treatment Adverse events, clinical remission, fecal calprotectin levels
FLORA Trial Advanced Liver Cancer Assess immunogenicity and safety of FMT combined with Atezolizumab/Bevacizumab CD8+ T cell infiltration, adverse events, overall survival
TransImmune Study Cirrhosis with Ascites Evaluate safety of FMT capsules for treating immune activation Serious adverse events, systemic inflammation markers, organ dysfunction scores

FAQ

  • What is Intestifix? Intestifix is a fecal microbiota transfer (FMT) treatment delivered in capsule form. It contains fecal microbiota from healthy donors, which is used to modify the gut microbiome of patients with various digestive and liver conditions.
  • What conditions are being studied with Intestifix? Clinical trials are investigating Intestifix for Crohn's disease, advanced liver cancer (hepatocellular carcinoma), and cirrhosis with ascites.
  • How is Intestifix administered? Intestifix is administered orally in capsule form. The dosage and frequency may vary depending on the specific trial and condition being studied.
  • What are the main objectives of these clinical trials? The main objectives include assessing the safety, feasibility, and efficacy of Intestifix for maintaining remission in Crohn's disease, overcoming resistance to cancer treatments, and treating immune activation in cirrhosis patients.
  • Are there any side effects associated with Intestifix? The clinical trials are designed to monitor and evaluate the safety of Intestifix, including the occurrence of adverse events. Specific side effects, if any, will be determined through these studies.

Ongoing Clinical Trials on Intestifix

  • Study on Fecal Microbiota Transfer for Preventing Recurrent Urinary Tract Infections in Premenopausal Women Using Intestifix

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness of Intestifix, Colistin Sulfate, and Vancomycin for Patients with Infections from Multidrug-Resistant Enterobacteriaceae

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study on Intestifix for Treating Immune Activation in Patients with Liver Cirrhosis and Ascites

    Recruiting

    2 1
    Investigated drugs:
    Germany

  • Study on Fecal Microbiota Transfer with Vancomycin, Atezolizumab, and Bevacizumab for Patients with Advanced Liver Cancer

    Recruiting

    2 1 1
    Investigated drugs:
    Germany

  • Study on INTESTIFIX for Maintaining Remission in Children and Adults with Crohn’s Disease After Exclusive Enteral Nutrition Treatment

    Recruiting

    1 1
    Investigated drugs:
    Germany

Glossary

  • Fecal Microbiota Transfer (FMT): A procedure in which fecal matter, or stool, is collected from a healthy donor, processed, and then transferred to a recipient to help restore a healthy balance of bacteria in the gut.
  • Crohn's Disease: A type of inflammatory bowel disease that causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
  • Hepatocellular Carcinoma: The most common type of primary liver cancer, often occurring in people with chronic liver diseases, such as cirrhosis.
  • Cirrhosis: A late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse.
  • Ascites: The accumulation of fluid in the abdominal cavity, often associated with liver disease and cirrhosis.
  • Remission: A period during a serious illness when symptoms become less severe or disappear.
  • Exclusive Enteral Nutrition (EEN): A dietary treatment that involves consuming only a liquid formula diet for a period of time, often used to induce remission in Crohn's disease.
  • Atezolizumab: A type of immunotherapy drug used to treat certain types of cancer, including liver cancer.
  • Bevacizumab: A targeted therapy drug that works by blocking the growth of new blood vessels, used in the treatment of various cancers, including liver cancer.
  • MELD Score: Model for End-Stage Liver Disease score, a numerical scale used to assess the severity of chronic liver disease and prioritize patients for liver transplantation.
  • Child-Pugh Score: A scoring system used to assess the prognosis of chronic liver disease, mainly cirrhosis.
  • Calprotectin: A protein released by white blood cells, often measured in stool samples to detect inflammation in the intestines.

References

  1. http://clinicaltrials.eu/trial/study-on-intestifix-for-maintaining-remission-in-children-and-adults-with-crohns-disease-after-exclusive-enteral-nutrition-treatment/
  2. http://clinicaltrials.eu/trial/study-on-fecal-microbiota-transfer-with-vancomycin-atezolizumab-and-bevacizumab-for-patients-with-advanced-liver-cancer/
  3. http://clinicaltrials.eu/trial/study-on-intestifix-for-treating-immune-activation-in-patients-with-liver-cirrhosis-and-ascites/